Sam Brusco, Associate Editor02.05.24
LivaNova has appointed Vladimir A. Makatsaria as its new CEO and a member of the board of directors. Makatsaria will take office on March 1, 2024.
He will succeed Bill Kozy, who has been LivaNova’s interim CEO since April 2023 when former CEO Damien McDonald resigned without reason. Kozy will remain in his role as board chair.
Boasting a nearly 30-year career in healthcare with executive leadership roles, Makatsaria was most recently company group chairman at Johnson & Johnson MedTech, leading its global Ethicon surgery business. He’s also served as chairman of the Asia Pacific Medical Technology Association (APACmed) and as an advisory board member to Singapore Management University.
“Vlad is a respected leader in the medical device industry with a proven reputation for delivering results, driving innovation and building great teams,” said Kozy. “The Board and I have great confidence that Vlad is the right CEO to advance the Company’s strategic plan and achieve our goals for long-term growth.”
“I look forward to working with the global team to deliver meaningful medical technologies to the patients we serve and to achieve LivaNova’s full potential,” added Makatsaria. “I would like to thank the Board of Directors and Bill Kozy for the opportunity to serve as CEO of LivaNova.”
Last month, LivaNova began an orderly wind down of its Advanced Circulatory Support (ACS) business to boost strategic focus on its core Cardiopulmonary and Neuromodulation businesses.
He will succeed Bill Kozy, who has been LivaNova’s interim CEO since April 2023 when former CEO Damien McDonald resigned without reason. Kozy will remain in his role as board chair.
Boasting a nearly 30-year career in healthcare with executive leadership roles, Makatsaria was most recently company group chairman at Johnson & Johnson MedTech, leading its global Ethicon surgery business. He’s also served as chairman of the Asia Pacific Medical Technology Association (APACmed) and as an advisory board member to Singapore Management University.
“Vlad is a respected leader in the medical device industry with a proven reputation for delivering results, driving innovation and building great teams,” said Kozy. “The Board and I have great confidence that Vlad is the right CEO to advance the Company’s strategic plan and achieve our goals for long-term growth.”
“I look forward to working with the global team to deliver meaningful medical technologies to the patients we serve and to achieve LivaNova’s full potential,” added Makatsaria. “I would like to thank the Board of Directors and Bill Kozy for the opportunity to serve as CEO of LivaNova.”
Last month, LivaNova began an orderly wind down of its Advanced Circulatory Support (ACS) business to boost strategic focus on its core Cardiopulmonary and Neuromodulation businesses.